Pulmonary Arterial Hypertension
526
52
72
270
Key Insights
Highlights
Success Rate
80% trial completion
Published Results
142 trials with published results (27%)
Research Maturity
270 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
12.9%
68 terminated out of 526 trials
79.9%
-6.7% vs benchmark
25%
129 trials in Phase 3/4
53%
142 of 270 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 270 completed trials
Clinical Trials (526)
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Spironolactone for Pulmonary Arterial Hypertension
Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
Extracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response in Systemic Sclerosis
Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)
Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO)
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
A Study of Pulmonary Hypertension Peripheral Limitations
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension